Key regions: United Kingdom, Brazil, Europe, France, Canada
The Anti-Fibrinolytic Drugs market in North America has been experiencing significant growth in recent years.
Customer preferences: One of the primary reasons for the growth of the Anti-Fibrinolytic Drugs market in North America is the increasing prevalence of bleeding disorders. Patients suffering from hemophilia and other bleeding disorders require medication to control their bleeding, and Anti-Fibrinolytic Drugs are an effective treatment option. Additionally, the aging population in North America has also contributed to the growth of the market, as older individuals are more likely to experience bleeding disorders.
Trends in the market: One major trend in the Anti-Fibrinolytic Drugs market in North America is the increasing use of these drugs in surgical procedures. Surgeons are using Anti-Fibrinolytic Drugs to reduce bleeding during and after surgery, which can improve patient outcomes and reduce the need for blood transfusions. Another trend is the development of new Anti-Fibrinolytic Drugs that are more effective and have fewer side effects than older medications.
Local special circumstances: The United States is the largest market for Anti-Fibrinolytic Drugs in North America, accounting for the majority of sales in the region. This is due in part to the high prevalence of bleeding disorders in the US, as well as the large number of surgical procedures performed in the country. Canada is also a significant market for Anti-Fibrinolytic Drugs, although it is smaller than the US market.
Underlying macroeconomic factors: The growth of the Anti-Fibrinolytic Drugs market in North America is also influenced by macroeconomic factors such as healthcare spending and government regulations. Increased healthcare spending in the region has made it possible for more patients to access Anti-Fibrinolytic Drugs, while government regulations have ensured that these medications are safe and effective for patients to use. Additionally, the presence of major pharmaceutical companies in North America has contributed to the development of new Anti-Fibrinolytic Drugs and the growth of the market overall.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
